**Analysis:**

The earnings call for Merck & Co. provided a mix of positive and negative signals. The company achieved strong financial results in 2016, with revenues of $39.8 billion and a non-GAAP EPS of $3.78, exceeding expectations. The company also provided positive guidance for 2017, with expected revenues ranging from $38.6 billion to $40.1 billion and EPS growth of 2% to 4%.

However, the call also highlighted several challenges and uncertainties. The company expects significant generic competition in 2017, which could impact its revenues. Additionally, the company's gross margin is expected to decrease due to the introduction of a new royalty on KEYTRUDA sales. The company also faces uncertainty around political and policy changes in the United States, which could impact its operations and growth prospects.

**Conclusion:**

The short-term impact on the stock price is likely to be neutral to slightly positive. The company's strong 2016 results and positive guidance for 2017 provide some upside potential. However, the challenges and uncertainties highlighted during the call could also weigh on the stock price in the short term. Overall, the stock is likely to experience moderate volatility in the next 1-2 weeks.

**Rating:** 1